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SUMMARY Cases of ischaemic heart disease have been studied for the cell-mediated immune response
against human heart antigen by using the leucocyte migration inhibition test. In 30 cases of acute
myocardial infarction, the leucocyte migration inhibition values started increasing from the first week
reaching a peak in 3 to 4 weeks and then declining but still above control values 12 months after infarction.
The leucocyte migration inhibition values were significantly higher than control values in another 10
patients with late complications of previous infarction and in those patients with acute myocardial
infarction who were less than 40 years of age, who had extensive anterior infarction, or who had a past
history ofangina pectoris. The leucocyte migration inhibition values were negligible in all the 12 patients
with stable angina pectoris, but were high in 2 of the 8 with unstable angina and in 3 of the 4 with the
intermediate coronary syndrome. The leucocyte migration inhibition values were muchhigher inpatients
with complications, which may be the result of cardiac damage by a cell-mediated immune response.
Humoral autoantibodies have been widely studied in
ischaemic heart disease (Gery et al., 1960; Ehrenfeld
et al., 1961; Van der Geld, 1964; Heine et al., 1966;
Strausz and Dobias, 1967; Sharma et al., 1970).
These antibodies are cytotoxic to myocardial cells
grown in tissue culture (Lotta, 1958; Thompson and
Halbert, 1971) and to myocardium on passive trans-
fer in experimental animals (Chaturvedi and
Mehrotra, 1967a). Development of anticardiac anti-
bodies in rats was shown as long ago as 1945 by
Cavelti, but cell-mediated immune response against
heart has only been demonstrated recently in experi-
mental animals (Chaturvedi and Mehrotra, 1967a, b;
Chaturvedi et al., 1971b). Little work has been done
on the cellular sensitisation which occurs in heart
disease. Cell-mediated immune response against rat
heart (Wartenberg and Brostoff, 1973) or human
heart antigens (Chaturvedi et al., 1977) has been
shown in cases of myocardial infarction by using the
leucocyte migration inhibition test. In the present
study an attempt was made to study the relation of
cell-mediated immune response to various clinical
presentations in cases of ischaemic heart disease.
Subjects and methods
Sixty-four patients with ischaemic heart disease
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were studied; these included 20 with angina pectoris,
4 with intermediate coronary syndrome, 30 with
acute myocardial infarction seen within 1 week of
onset, and 10 with old myocardial infarction (3 to 12
months after acute illness). There were 60 men and 4
women, aged 30 to 91 years (Table 1). Angina
pectoris was diagnosed when a patient gave a history
of ischaemic cardiac pain, usually lasting for 3 to 5
minutes and in some cases 10 to 20 minutes but
never more than 30 minutes; the electrocardiograms
at rest or after exercise showed evidence of myo-
cardial ischaemia. The patients with intermediate
coronary syndrome had had prolonged ischaemic
cardiac pain lasting for more than 30 minutes but
had no evidence of myocardial necrosis on serial 12-
lead electrocardiograms or aspartate aminotrans-
ferase estimations performed during the following 3
days. Acute myocardial infarction was diagnosed in
those with a history of prolonged ischaemic cardiac
pain; the electrocardiogram showed pathological Q
waves and characteristic ST segment and T wave
changes. The old myocardial infarction cases were
those who had suffered from proven acute myo-
cardial infarction 3 to 12 months earlier. The
patients with angina pectoris were classed as stable
or unstable (Desai and Alexander, 1972). Angina
was regarded as stable when symptoms in a given
patient were predictably produced on exertion and
relieved by rest or glyeryl trinitrate or other similar
drugs. These patients had had angina for 6 months
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Table 1 Age and sex distribution of the cases
Total no. of Sex Age
cases
Males Females 30-40 41-50 51-60 61-70 > 71 Mean
Study group
Angina pectoris 20 20 - 2 8 8 2 - 50 7
Intermediate
coronary syndrome 4 4 - 1 2 1 - - 46-0
Myocardial
infarction 40 36 4 6 16 13 3 2 50 5
Total 64 60 4 9 26 22 5 2 50 4
Control group 20 18 2 5 8 5 1 1 48-9
or more, more or less constant in severity for at least
1 month. Angina was said to have become unstable
when there had been a change in symptom pattern;
pain was more easily provoked and/or started occurr-
ing spontaneously and lasted longer, and the pre-
viously successful methods of relieving pain were no
longer effective. Associated risk factors, viz. diabetes
mellitus, hypertension, hyperlipidaemia, positive
family history, and smoking, were identified (Table
2). Cases of myocardial infarction were differen-
tiated into anterior (including extensive anterior-
Friedman, 1971) and inferior and/or posterior
myocardial infarction; a note was also made of
complications and past history of angina pectoris.
The control group consisted of 20 healthy, age-
matched individuals who had no clinical, radio-
logical, or electrocardiographic evidence of any heart
disease.
LEUCOCYTE MIGRATION INHIBITION TEST
The heart of a 36-year-old man who died in a road
accident was removed within 2 hours of death. The
heart was cut in thin slices, washed with sterile
phosphate buffered saline, and stored at - 20°C. A
10 per cent heart extract was prepared in PBS and
was used as antigen (Chaturvedi et al., 1973b).
In the 30 acute myocardial infarct patients, the
leucocyte migration inhibition test was done on
heparinised blood collected at 1, 2, 3, and 4 weeks
and 3, 6, and 12 months after infarction.
The leucocytes were separated from the plasma,
washed thrice with Hank's basal salt solution, and
introduced into glass capillary tubes, one end of
which was sealed by heat; the tubes were centri-
fuged at 500 rpm for 20 minutes and then cut at the
cell-fluid interphase, the portion containing cells
being fixed in paraffin wax in migration chambers.
The chambers were filled with medium miniimum
essential (Eagle's) containing 10 per cent newborn
calf serum. The antigen (heart extract) was added to
one set of chambers while another set remained
without antigen for control. The optimum dose of
antigen was determined in pilot experiments. The
tests were done in triplicate both in controls and in
the cases in the study group. The chambers were
incubated at 37°C for 20 hours. The area of cell
migration was drawn on Whatman No. 1 chromato-
graphic paper with Camera Lucida using a magni-
fication of x 15. The area of migration on paper was
cut and weighed on a precision balance. The results
were expressed as per cent inhibition of leucocyte
migration (LMI %) in the presence of antigen,
according to the following formula:
LMI (%) =
Migration without antigen - Migration with antigen
Migration without antigen
x 100.
A migration inhibition of 20 per cent or more was
considered significant (Oritz-Oritz et al., 1974).
Table 2 Analysis of risk factors
Group Total no. of No. of cases Total no. of No. with various risk factors
cases without risk cases with risk
factors factors + ve Diabetes Hyper- Hyper- Obesity Smoking
family mellitus tension lipidaemia
history
Angina peztoris 20 12 8 1 2 2 - 1 5
Intermediate
coronary syndrome 4 2 2 - 1 - 1 - 2
Myocardial
infarction 40 26 14 3 6 3 2 3 9
Total 64 40 24 4 9 5 3 4 16
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Fig. 1 Leucocyte migration inhibition in healthy
controls (C), cases of stable angina pectoris (SA),
unstable angina pectoris (UA), and intermediate
coronary syndrome (IC): each point represents the mean
of 3 estimations.
Results
In healthy controls the mean leucocyte migration
inhibition was 2 ± 1 per cent. There was no sig-
nificant relation between leucocyte migration inhibi-
tion and age or sex in the control cases. In cases of
stable angina mean leucocyte migration inhibition
was 5 ± 3 per cent and in unstable angina 16 ± 5
per cent (Fig. 1). Two of the 8 cases of unstable
angina had leucocyte migration inhibition values
above 20 per cent (21 and 22%) but the other 6 had
lower values. Four cases ofthe intermediate coronary
syndrome had leucocyte migration inhibition values
of 32, 29, 27, and 17 per cent, with a mean value of
26 + 6 (Fig. 1).
The cases of myocardial infarction were studied
in greater detail and an attempt was made to cor-
relate the leucocyte migration inhibition values with
various possibly relevant factors.
TIME AFTER MYOCARDIAL INFARCTION
The results are presented in Fig. 2. The mean
leucocyte migration inhibition value was 22 ± 8 per
cent in the first week, 50 ± 15 per cent in the second
week, 69 ± 8 per cent in the third week, 70 ± 9 per
cent in the fourth week, 55 ± 8 per cent in the third
month, 45 ± 14 per cent in the sixth month, and 39 ±
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Fig. 2 Leucocyte migration inhibition in healthy
controls (C) and at different times after acute
myocardial infarction.
20 per cent in the twelfth month. It is evident from
Fig. 2 that inhibition of leucocyte migration
increased during the first 3 or 4 weeks reaching a
peak value at that time, then gradually declined from
the third to the twelfth month after myocardial
infarction.
In the following paragraphs, the peak leucocyte
migration inhibition value during the initial 4-week
period has been related to the various factors.
AGE OF PATIENT
There were significantly higher leucocyte migration
inhibition values in patients between 30 and 40 years
of age than in those over 40 years (P < 005) (Table
3).
SITE OF MYOCARDIAL INFARCTION
The relation of the site of infarction and leucocyte
migration inhibition is summarised in Fig. 3. The
mean leucocyte migration inhibition value was
Table 3 Relation of mean leucocyte migration inhibition
(LMI) to age of patients with acute myocardial infarction
Age (y) No. of cases Mean LMI ± SD
30-40 5 77 ± 5*
41-50 13 68 i 9
51-60 9 72 ± 11
61-70 2 64
71-91 1 64
*Difference between mean value for patients aged 30 to 40 years
significantly different from mean value for patients over 40 years
(P < 0 05).
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Fig. 3 Leucocyte migration inhibition in relation to site
and extent of infarction. (A) Anterior infarction, (B)
inferior/posterior infarction, (C) extensive anterior
infarction, and (D) remaining anterior infarctionl
inferior/posterior infarction.
71 + 10 and 70 + 10 per cent in cases of anterior
infarction and inferior/posterior infarction, respec-
tively (P > 0 05). However, the cases of extensive
anterior infarction showed 78 ± 7 per cent inhibi-
tion of leucocyte migration, compared with 68 + 10
per cent inhibition ofmigration in all other infarction
cases (P < 0.01).
RISK FACTORS
The risk factors taken into account were diabetes
mellitus, hypertension, hyperlipidaemia, smoking,
and positive family history. Mean leucocyte migra-
tion inhibition values in 11 cases of acute myocardial
infarction with risk factors and in 19 cases without
risk factors were 68 + 9 and 71 ± 10 per cent,
respectively (P > 0 05) (Fig. 4).
HISTORY OF ANGINA PECTORIS
Seven patients had had angina for 6 months or more.
The mean leucocyte migration inhibition value in
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Fig. 4 Leucocyte migration inhibition in cases of acute
myocardial infarction, (A) with risk factors, (B) without
risk factors, (C) with past history of angina pectoris, and
(D) without past history of angina pectoris.
such patients was 82 ± 8 per cent, while in another
23 patients who never had angina it was 67 + 8 per
cent (Fig. 4). The difference between these two
groups is significant (P < 0 001).
COMPLICATIONS
Twelve patients with acute myocardial infarction
had various complications (arrhythmias, left ven-
tricular failure, congestive heart failure, or peri-
carditis). The mean leucocyte migration inhibition
value in such patients was 67 ± 9 per cent (Table 4)
and in the 18 cases with no complications the mean
leucocyte migration inhibition value was 72 + 10
per cent (P > 0.05). Myocardial infarct patients
who were readmitted with angina, congestive heart
failure, left ventricular failure, the shoulder hand
syndrome, or Dressler's syndrome, 3 or 12 months
after the initial illness, had mean leucocyte migration
inhibition values significantly higher than those in
uncomplicated cases (Table 4).
Table 4 Relation of leucocyte migration inhibition (LMI) to complications of myocardial infarction
Acute infarction Old myocardial infarction*
No. of cases LMI ± SD 3 months 6 months 12 months
No. of cases LMI ± SD No. of cases LMI ± SD No. of cases LMI + SD
Uncomplicated 18 72 + 10 11 52 ± 7 8 35 ± 14 5 25 ± 6
Complicated 12 67 ± 9 4 64 ± 4 4 61 ± 3 3 64 ± 6
P value > 005 <005 <0-001 <0-001
*This group includes patients originally seen as cases of acute myocardial infarction who had late complications, as well as those seen for the
first time 3 to 12 months after their acute myocardial infarct.
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Discussion
In the present study, myocardial infarct patients
showed significant leucocyte migration inhibition
which increased to a peak value 3 or 4 weeks after
infarction and then declined, but which could still
be shown after 12 months. Similarly, titres of
humoral anticardiac antibodies are greatest 3 weeks
after myocardial infarction (Sharma et al., 1970).
Also, in serial experimental studies peak values of
humoral antibodies and cell mediated immune
response were found 3 to 4 weeks after pen-
cardiotomy (Chaturvedi et al., 1973a). Wartenberg
and Brostoff (1973) found significant leucocyte
migration inhibition in all the 14 patients studied
within 2 weeks and in 2 cases studied 3 to 4 weeks
after myocardial infarction; their failure to show a
correlation between leucocyte migration inhibition
and time after infarction may be the result of the
smaller number of patients and fewer observations
on each patient.
The patients with stable angina pectoris showed
insignificant leucocyte migration inhibition (5 +
3%). Two of the 8 patients with unstable angina
pectoris had more than 20 per cent leucocyte
migration inhibition (21 and 22%). Wartenberg and
Brostoff (1973) studied 2 cases of angina pectoris
and found significant inhibition of leucocyte
migration. Of 4 patients with the intermediate
coronary syndrome, 3 showed significant leucocyte
migration inhibition (mean 26 ± 6%). Humoral
antibodies have been found in 42 to 63 per cent of
cases with angina pectoris (Davies and Gery, 1960;
Heine et al., 1966; Strausz and Dobias, 1967; Das
et al., 1974). These observations indicate release of
cardiac antigens in such patients, which may be the
result of necrosis of myocardial fibres (Hurst et al.,
1974).
Significantly higher leucocyte migration inhibition
values were found in patients below the age of 40
years, with extensive anterior infarction, past history
ofangina pectoris, or late complications ofinfarction.
The presence of coronary risk factors or complica-
tions of acute myocardial infarction did not affect
the leucocyte migration inhibition values.
It was interesting to find that there were signifi-
cantly higher leucocyte migration inhibition values
in 11 myocardial infarct patients with late com-
plications, including 3 with postinfarction angina,
and 1 each of Dressler's syndrome and the shoulder
hand syndrome. These higher leucocyte migration
inhibition values may be the result of increased and/
or recurrent release of cardiac antigens and conse-
quent great sensitisation of T-cells. On the other
hand, the sensitised T-cells may be damaging the
heart thus causing these manifestations. The higher
leucocyte migration inhibition values may reflect
greater T-cell activity. There is evidence that anti-
bodies are produced as a result of cardiac injury
(Chaturvedi, 1974). Antibodies may thus be pro-
duced as a result of myocardial infarction. Since
anticardiac antibodies (both humoral and cellular)
have been shown to produce cardiac damage on pas-
sive transfer to normal animals (Chaturvedi and
Mehrotra, 1967a), it is likely that the above-
mentioned complications may be caused by these
antibodies.
It is interesting to speculate on why complications
occur in some cases and not in others. This may
depend upon certain factors which may potentiate
cardiotoxic effects of antibodies: two of these have
been reported in experimental studies, isoprenaline
(Chaturvedi and Mehrotra, 1969), and Coxsackie B4
infection (Chaturvedi et al., 1971a), but it is not
known how far these experimental observations can
be extrapolated to human patients.
Bauer et al. (1972) found no difference in anti-
cardiac antibody titres in complicated compared
with uncomplicated cases of myocardial infarction.
There was no relation between antibody titre and the
occurrence of the post-cardiotomy syndrome
(to be published). It may, therefore, be that
the cell-mediated immune response is more import-
ant as a cause of cardiac damage; this view is sup-
ported by observations in experimental animals
(Natu and Chaturvedi, 1977).
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